Esperion Therapeutics (ESPR) Equity Average (2018 - 2025)
Historic Equity Average for Esperion Therapeutics (ESPR) over the last 8 years, with Q3 2025 value amounting to -$442.4 million.
- Esperion Therapeutics' Equity Average fell 2385.7% to -$442.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$442.4 million, marking a year-over-year decrease of 2385.7%. This contributed to the annual value of -$421.9 million for FY2024, which is 833.93% down from last year.
- As of Q3 2025, Esperion Therapeutics' Equity Average stood at -$442.4 million, which was down 2385.7% from -$429.9 million recorded in Q2 2025.
- Over the past 5 years, Esperion Therapeutics' Equity Average peaked at -$182.8 million during Q1 2021, and registered a low of -$442.4 million during Q3 2025.
- Over the past 5 years, Esperion Therapeutics' median Equity Average value was -$333.5 million (recorded in 2021), while the average stood at -$336.3 million.
- In the last 5 years, Esperion Therapeutics' Equity Average plummeted by 172785.23% in 2021 and then surged by 1226.21% in 2024.
- Over the past 5 years, Esperion Therapeutics' Equity Average (Quarter) stood at -$279.8 million in 2021, then fell by 10.4% to -$308.9 million in 2022, then crashed by 39.99% to -$432.5 million in 2023, then rose by 12.26% to -$379.5 million in 2024, then fell by 16.59% to -$442.4 million in 2025.
- Its Equity Average stands at -$442.4 million for Q3 2025, versus -$429.9 million for Q2 2025 and -$407.5 million for Q1 2025.